Johnson Matthey and Immunomedics join forces on cancer treatment

By Sophie Bullimore 16-Jan-2019

A strategic manufacturing partnership has been announced for key ingredient of FDA priority review candidate

Johnson Matthey and Immunomedics have collaborated to produce an ingredient in Immunomedics’ cancer treatment. Immunomedics is a clinical-stage biopharmaceutical company. It will use Johnson Matthey’s high potency GMP manufacturing capabilities to produce a cancer drug.

The drug at the root of the manufacturing partnership is an antibody-drug conjugate, currently under priority review with the FDA.

The drug requires a drug-linker. UK-based Johnson Matthey, a science and chemical production company, will be producing the drug-linker at its Massachusetts facility. This is a location convenient to the agreement as Immunomedics is headquartered in the US.

Johnson Matthey has taken on the scale-up function in this partnership, as it has in many collaborations previously, celebrating its 200th anniversary in 2017.

Nick Shackley, Vice President, Health of Johnson Matthey: said: “We are proud to build on our existing relationship with Immunomedics to enable the production of viable treatment options to improve cancer patients’ lives.”

Sign up for your free email newsletter

The antibody-drug conjugate, called sacituzumab govitecan, is a drug developed for the treatment of patients with metastatic triple-negative breast cancer. If approved this would be the first therapy accepted for this patient group.

Companies